Dr Helen Parry MBChB, MSc, PhD, MRCP, FRCPath

Dr Helen Parry

Institute of Immunology and Immunotherapy
NIHR Clinical Lecturer

Contact details

Telephone
+44 (0)121 414 44477
Email
h.m.parry@bham.ac.uk
Twitter
@low_helen
View my research portal
Address
Institute of Immunology and Immunotherapy
Cancer Sciences Building
Mindelsohn Way
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Dr Helen Parry is a National Institute for Health Research (NIHR) academic clinical lecturer and works between the University of Birmingham and Queen Elizabeth Hospital, Birmingham. She has received funding from The Wellcome Trust (PhD fellowship), Academy of medical sciences (current), British Society of Haematology (current) and Queen Elizabeth Hospital charity (current education grant) funding.

Her current research areas include secondary immunodeficiency in haematological malignancies, and in particular Chronic Lymphocytic Leukaemia (CLL), for which she co-authored the British clinical guidelines. Her work involves studying patient immunity and the impact of novel therapies used to treat CLL and how we can improve current vaccination strategies to minimise infection risk. She is also interested in optimising the delivery of haematology services within a primary care setting and has an interest in medical education, being the co-founder of Blooducation. 

Qualifications

  • FRCPath 2018
  • PhD, University of Birmingham 2016
  • MRCP (UK) 2009
  • MBChB (Hons) University of Birmingham 2006
  • MSc (Distinction) in pathological studies, University of Birmingham 2005

Teaching

  • MBChB programme – Immunology and infection module; cancer module
  • Supervisor for intercalating BSc students

Research

Research themes:

  • Optimising vaccination strategies and minimising infection risk in patients with CLL
  • Investigating immunity in the setting of novel therapeutic agents

Publications

Recent publications

Article

Parry, H, McIlroy, G, Bruton, R, Ali, M, Stephens, C, Damery, S, Otter, A, McSkeane, T, Rolfe, H, Faustini, S, Wall, N, Hillmen, P, Pratt, G, Paneesha, S, Zuo, J, Richter, A & Moss, P 2021, 'Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia', Blood Cancer Journal, vol. 11, no. 7, 136. https://doi.org/10.1038/s41408-021-00528-x

Parry, HM, Dowell, AC, Zuo, J, Verma, K, Kinsella, FAM, Begum, J, Croft, W, Sharma-Oates, A, Pratt, G & Moss, P 2021, 'PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity', PLoS pathogens, vol. 17, no. 3, e1009349. https://doi.org/10.1371/journal.ppat.1009349

Mato, AR, Roeker, LE, Jacobs, R, Hill, BT, Lamanna, N, Brander, D, Shadman, M, Ujjani, CS, Yazdy, MS, Perini, GF, Pinilla-ibarz, JA, Barrientos, J, Skarbnik, AP, Torka, P, Pu, JJ, Pagel, JM, Gohil, S, Fakhri, B, Choi, M, Coombs, CC, Rhodes, J, Barr, PM, Portell, CA, Parry, H, Garcia, CA, Whitaker, KJ, Winter, AM, Sitlinger, A, Khajavian, S, Grajales-cruz, AF, Isaac, KM, Shah, P, Akhtar, OS, Pocock, R, Lam, K, Voorhees, TJ, Schuster, SJ, Rodgers, TD, Fox, CP, Martinez-calle, N, Munir, T, Bhavsar, EB, Bailey, N, Lee, JC, Weissbrot, HB, Nabhan, C, Goodfriend, JM, King, AC, Zelenetz, AD, Dorsey, C, Bigelow, K, Cheson, BD, Allan, JN & Eyre, TA 2020, 'Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy', Clinical Cancer Research, vol. 26, no. 14, pp. 3589-3596. https://doi.org/10.1158/1078-0432.CCR-19-3815

Kwok, MCK, Oldreive, C, Rawstron, AC, Goel, A, Papatzikas, G, Jones, R, Drennan, S, Agathanggelou, A, Sharma-Oates, A, Evans, P, Smith, E, Dalal, S, Mao, J, Hollows, R, Gordon, N, Hamada, M, Davies, N, Parry, H, Beggs, A, Munir, T, Moreton, P, Paneesha, S, Pratt, G, Taylor, M, Forconi, F, Baird, D, Cazier, J-B, Moss, P, Hillmen, P & Stankovic, T 2020, 'Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL: natural history and mechanism of spontaneous CLL regression', Blood, vol. 135, no. 6, pp. 411-428. https://doi.org/10.1182/blood.2019001262

Mato, AR, Roeker, LE, Lamanna, N, Allan, JN, Leslie, L, Pagel, JM, Patel, K, Osterborg, A, Wojenski, D, Kamdar, M, Huntington, SF, Davids, MS, Brown, JR, Antic, D, Jacobs, R, Ahn, IE, Pu, J, Isaac, KM, Barr, PM, Ujjani, CS, Geyer, MB, Berman, E, Zelenetz, AD, Malakhov, N, Furman, RR, Koropsak, M, Bailey, N, Hanson, L, Perini, GF, Ma, S, Ryan, CE, Wiestner, A, Portell, CA, Shadman, M, Chong, EA, Brander, DM, Sundaram, S, Seddon, AN, Seymour, E, Patel, M, Martinez-calle, N, Munir, T, Walewska, R, Broom, A, Walter, H, El-sharkawi, D, Parry, H, Wilson, MR, Patten, PEM, Hernández-rivas, J, Miras, F, Fernández Escalada, N, Ghione, P, Nabhan, C, Lebowitz, S, Bhavsar, E, López-jiménez, J, Naya, D, Garcia-marco, JA, Skånland, SS, Cordoba, R & Eyre, TA 2020, 'Outcomes of COVID-19 in patients with CLL: a multicenter international experience', Blood, vol. 136, no. 10, pp. 1134-1143. https://doi.org/10.1182/blood.2020006965

Parry, HM, Mirajkar, N, Cutmore, N, Zuo, J, Long, H, Kwok, M, Oldrieve, C, Hudson, C, Stankovic, T, Paneesha, S, Kelly, M, Begum, J, McSkeane, T, Pratt, G & Moss, P 2019, 'Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia', Frontiers in immunology, vol. 10, 2832. https://doi.org/10.3389/fimmu.2019.02832

Schuh, AH, Parry-Jones, N, Appleby, N, Bloor, A, Dearden, CE, Fegan, C, Follows, G, Fox, CP, Iyengar, S, Kennedy, B, McCarthy, H, Parry, HM, Patten, P, Pettitt, AR, Ringshausen, I, Walewska, R & Hillmen, P 2018, 'Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline', British Journal of Haematology, vol. 182, no. 3, pp. 344-359. https://doi.org/10.1111/bjh.15460

Zuo, J, Willcox, C, Mohammed, F, Davey, M, Hunter, S, Khan, K, Antoun , A, Katakia, P, Croudace, J, Inman, C, Parry, H, Briggs, D, Malladi, R, Willcox, B & Moss, P 2017, 'A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding', Science signaling, vol. 10, no. 481, eaai8904. https://doi.org/10.1126/scisignal.aai8904

Davies, N, Kwok, M, Gould, C, Oldreive, C, Mao, J, Parry, H, Smith, E, Agathanggelou, A, Pratt, G, Taylor, M, Moss, P, Griffiths, M & Stankovic, T 2017, 'Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts', OncoTarget, vol. 8, no. 27, pp. 44749-44760. https://doi.org/10.18632/oncotarget.17432

Agathanggelou, A, Smith, E, Davies, N, Kwok, M, Zlatanou, A, Oldreive, C, Mao, J, Da Costa, D, Yadollahi, S, Perry, T, Kearns, P, Skowronska, A, Yates, E, Parry, H, Hillmen, P, Reverdy, C, Delansorne, R, Paneesha, S, Pratt, G, Moss, P, Taylor, M, Stewart, G & Stankovic, T 2017, 'USP7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM/p53 functional status', Blood, vol. 130, no. 2, pp. 156–166. https://doi.org/10.1182/blood-2016-12-758219

Kwok, M, Davies, N, Agathanggelou, A, Smith, E, Oldreive, C, Petermann, E, Stewart, G, Brown, J, Lau, A, Pratt, G, Parry, H, Taylor, M, Moss, P, Hillmen, P & Stankovic, T 2016, 'ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells', Blood, vol. 127, no. 5, pp. 582-595. https://doi.org/10.1182/blood-2015-05-644872

Parry, H, Damery, S, Hudson, C, Maurer, M, Cerhan, J, Pachnio, A, Begum, J, Slager, S, Fegan, C, Man, S, Pepper, C, Shanafelt, T, Pratt, G & Moss, P 2016, 'Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia', American Journal of Haematology, vol. 91, no. 8, pp. 776–781. https://doi.org/10.1002/ajh.24403

Parry, HM, Zuo, J, Frumento, G, Mirajkar, N, Inman, C, Edwards, E, Griffiths, M, Pratt, G & Moss, P 2016, 'Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years', Immunity & Ageing, vol. 13, 1. https://doi.org/10.1186/s12979-015-0056-6

Pratt, G, Thomas, P, Marden, N, Alexander, D, Davis, Z, Hussey, D, Parry, H, Harding, S, Catovsky, D, Begley, J & Oscier, D 2016, 'Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival', Leukemia and Lymphoma, vol. 57, no. 10, pp. 2342-2350. https://doi.org/10.3109/10428194.2015.1137291

Koczula, KM, Ludwig, C, Hayden, R, Cronin, L, Pratt, G, Parry, H, Tennant, D, Drayson, M, Bunce, CM, Khanim, FL & Günther, UL 2016, 'Metabolic plasticity in CLL: adaptation to the hypoxic niche', Leukemia, vol. 30, no. 1, pp. 65–73. https://doi.org/10.1038/leu.2015.187

View all publications in research portal